Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exploratory, Phase II, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GLPG0974 in Subjects With Mild to Moderate Ulcerative Colitis.

Next Previous
Trial Profile

Exploratory, Phase II, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GLPG0974 in Subjects With Mild to Moderate Ulcerative Colitis.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GLPG 0974 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Galapagos NV; Lakefront Biotherapeutics

Most Recent Events

  • 12 Jun 2026 According to Galapagos NV media release, Galapagos NV is now called Lakefront Biotherapeutics.
  • 24 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 18 Feb 2014 Planned End Date in the ClinicalTrials.gov record has been changed from 1 January 2014 to 1 May 2014.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top